Selected research
Industry Research
Medications for Chronic Pain Treatment Industry Research Report 2026
Market perspective
The global Medications for Chronic Pain Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Medications for Chronic Pain Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Medications for Chronic Pain Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Medications for Chronic Pain Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Medications for Chronic Pain Treatment include YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD., Southwest Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., REYOUNG, Johnson and Johnson Services Inc., Novartis AG, Merck & Co., Jiangsu Hengrui Medicine Co,.Ltd and Pfizer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Medications for Chronic Pain Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Medications for Chronic Pain Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medications for Chronic Pain Treatment Market by Company
YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
Southwest Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
REYOUNG
Johnson and Johnson Services Inc.
Novartis AG
Merck & Co.
Jiangsu Hengrui Medicine Co,.Ltd
Pfizer
GlaxoSmithKline plc.
BAYER
AstraZeneca plc.
Purdue Pharma L.P.
Endo International plc.
Depomed
Abbott Laboratories
Medications for Chronic Pain Treatment Segment by Type
Nonopioid
Opioids
Medications for Chronic Pain Treatment Segment by Application
Hospital
Pharmacy
Other
Medications for Chronic Pain Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Chronic Pain Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medications for Chronic Pain Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Chronic Pain Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Medications for Chronic Pain Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nonopioid
- Opioids
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
- Southwest Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- REYOUNG
- Johnson and Johnson Services Inc.
- Novartis AG
- Merck & Co.
- Jiangsu Hengrui Medicine Co,.Ltd
- Pfizer
- GlaxoSmithKline plc.
- BAYER
- AstraZeneca plc.
- Purdue Pharma L.P.
- Endo International plc.
- Depomed
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Medications for Chronic Pain Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Nonopioid
- 2.2.3 Opioids
- 2.3 Medications for Chronic Pain Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Medications for Chronic Pain Treatment Breakdown Data by Type
- 3.1 Global Medications for Chronic Pain Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Medications for Chronic Pain Treatment Forecasted Market Size by Type (2027-2032)
4 Medications for Chronic Pain Treatment Breakdown Data by Application
- 4.1 Global Medications for Chronic Pain Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Medications for Chronic Pain Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Medications for Chronic Pain Treatment Market Perspective (2021-2032)
- 5.2 Global Medications for Chronic Pain Treatment Growth Trends by Region
- 5.2.1 Global Medications for Chronic Pain Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Medications for Chronic Pain Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Medications for Chronic Pain Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Medications for Chronic Pain Treatment Market Dynamics
- 5.3.1 Medications for Chronic Pain Treatment Industry Trends
- 5.3.2 Medications for Chronic Pain Treatment Market Drivers
- 5.3.3 Medications for Chronic Pain Treatment Market Challenges
- 5.3.4 Medications for Chronic Pain Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Medications for Chronic Pain Treatment Players by Revenue
- 6.1.1 Global Top Medications for Chronic Pain Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Medications for Chronic Pain Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Medications for Chronic Pain Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Medications for Chronic Pain Treatment Head Office and Area Served
- 6.4 Global Medications for Chronic Pain Treatment Players, Product Type & Application
- 6.5 Global Medications for Chronic Pain Treatment Manufacturers Established Date
- 6.6 Global Medications for Chronic Pain Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Medications for Chronic Pain Treatment Market Size (2021-2032)
- 7.2 North America Medications for Chronic Pain Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Medications for Chronic Pain Treatment Market Size by Country (2021-2026)
- 7.4 North America Medications for Chronic Pain Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Medications for Chronic Pain Treatment Market Size (2021-2032)
- 8.2 Europe Medications for Chronic Pain Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Medications for Chronic Pain Treatment Market Size by Country (2021-2026)
- 8.4 Europe Medications for Chronic Pain Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Medications for Chronic Pain Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Medications for Chronic Pain Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Medications for Chronic Pain Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Medications for Chronic Pain Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Medications for Chronic Pain Treatment Market Size (2021-2032)
- 10.2 South America Medications for Chronic Pain Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Medications for Chronic Pain Treatment Market Size by Country (2021-2026)
- 10.4 South America Medications for Chronic Pain Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Medications for Chronic Pain Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Medications for Chronic Pain Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Medications for Chronic Pain Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Medications for Chronic Pain Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
- 12.1.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Company Information
- 12.1.2 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Business Overview
- 12.1.3 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.1.4 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Product Portfolio
- 12.1.5 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Recent Developments
- 12.2 Southwest Pharmaceutical Co., Ltd.
- 12.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
- 12.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
- 12.2.3 Southwest Pharmaceutical Co., Ltd. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.2.4 Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Product Portfolio
- 12.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
- 12.3 Teva Pharmaceutical Industries Ltd.
- 12.3.1 Teva Pharmaceutical Industries Ltd. Company Information
- 12.3.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 12.3.3 Teva Pharmaceutical Industries Ltd. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.3.4 Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Product Portfolio
- 12.3.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 12.4 REYOUNG
- 12.4.1 REYOUNG Company Information
- 12.4.2 REYOUNG Business Overview
- 12.4.3 REYOUNG Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.4.4 REYOUNG Medications for Chronic Pain Treatment Product Portfolio
- 12.4.5 REYOUNG Recent Developments
- 12.5 Johnson and Johnson Services Inc.
- 12.5.1 Johnson and Johnson Services Inc. Company Information
- 12.5.2 Johnson and Johnson Services Inc. Business Overview
- 12.5.3 Johnson and Johnson Services Inc. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.5.4 Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Product Portfolio
- 12.5.5 Johnson and Johnson Services Inc. Recent Developments
- 12.6 Novartis AG
- 12.6.1 Novartis AG Company Information
- 12.6.2 Novartis AG Business Overview
- 12.6.3 Novartis AG Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.6.4 Novartis AG Medications for Chronic Pain Treatment Product Portfolio
- 12.6.5 Novartis AG Recent Developments
- 12.7 Merck & Co.
- 12.7.1 Merck & Co. Company Information
- 12.7.2 Merck & Co. Business Overview
- 12.7.3 Merck & Co. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.7.4 Merck & Co. Medications for Chronic Pain Treatment Product Portfolio
- 12.7.5 Merck & Co. Recent Developments
- 12.8 Jiangsu Hengrui Medicine Co,.Ltd
- 12.8.1 Jiangsu Hengrui Medicine Co,.Ltd Company Information
- 12.8.2 Jiangsu Hengrui Medicine Co,.Ltd Business Overview
- 12.8.3 Jiangsu Hengrui Medicine Co,.Ltd Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.8.4 Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Product Portfolio
- 12.8.5 Jiangsu Hengrui Medicine Co,.Ltd Recent Developments
- 12.9 Pfizer
- 12.9.1 Pfizer Company Information
- 12.9.2 Pfizer Business Overview
- 12.9.3 Pfizer Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.9.4 Pfizer Medications for Chronic Pain Treatment Product Portfolio
- 12.9.5 Pfizer Recent Developments
- 12.10 GlaxoSmithKline plc.
- 12.10.1 GlaxoSmithKline plc. Company Information
- 12.10.2 GlaxoSmithKline plc. Business Overview
- 12.10.3 GlaxoSmithKline plc. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.10.4 GlaxoSmithKline plc. Medications for Chronic Pain Treatment Product Portfolio
- 12.10.5 GlaxoSmithKline plc. Recent Developments
- 12.11 BAYER
- 12.11.1 BAYER Company Information
- 12.11.2 BAYER Business Overview
- 12.11.3 BAYER Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.11.4 BAYER Medications for Chronic Pain Treatment Product Portfolio
- 12.11.5 BAYER Recent Developments
- 12.12 AstraZeneca plc.
- 12.12.1 AstraZeneca plc. Company Information
- 12.12.2 AstraZeneca plc. Business Overview
- 12.12.3 AstraZeneca plc. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.12.4 AstraZeneca plc. Medications for Chronic Pain Treatment Product Portfolio
- 12.12.5 AstraZeneca plc. Recent Developments
- 12.13 Purdue Pharma L.P.
- 12.13.1 Purdue Pharma L.P. Company Information
- 12.13.2 Purdue Pharma L.P. Business Overview
- 12.13.3 Purdue Pharma L.P. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.13.4 Purdue Pharma L.P. Medications for Chronic Pain Treatment Product Portfolio
- 12.13.5 Purdue Pharma L.P. Recent Developments
- 12.14 Endo International plc.
- 12.14.1 Endo International plc. Company Information
- 12.14.2 Endo International plc. Business Overview
- 12.14.3 Endo International plc. Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.14.4 Endo International plc. Medications for Chronic Pain Treatment Product Portfolio
- 12.14.5 Endo International plc. Recent Developments
- 12.15 Depomed
- 12.15.1 Depomed Company Information
- 12.15.2 Depomed Business Overview
- 12.15.3 Depomed Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.15.4 Depomed Medications for Chronic Pain Treatment Product Portfolio
- 12.15.5 Depomed Recent Developments
- 12.16 Abbott Laboratories
- 12.16.1 Abbott Laboratories Company Information
- 12.16.2 Abbott Laboratories Business Overview
- 12.16.3 Abbott Laboratories Revenue in Medications for Chronic Pain Treatment Business (2021-2026)
- 12.16.4 Abbott Laboratories Medications for Chronic Pain Treatment Product Portfolio
- 12.16.5 Abbott Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst